Literature DB >> 1676658

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations.

S P Khor1, M Mayersohn.   

Abstract

Physiological pharmacokinetic models require the determination of tissue to blood distribution coefficients. A theoretical model has been developed and the resulting equations indicate that under certain conditions it is necessary to correct for the presence of drug in the residual blood remaining in the tissue. The potential error in ignoring this residual blood is expressed mathematically in terms of several important factors that include the anatomical features of the tissue (volume fractions of the blood, interstitial fluid, and cellular space) as well as the physicochemical properties of the drug (extent of binding in the blood and tissues). These theoretical considerations and resulting simulations have been applied to experimental literature data for several compounds (methotrexate, digoxin, and biperiden). We conclude that correction for the residual blood is necessary when the values of tissue to blood distribution coefficients are very small or large (relative to one) and when the volume fraction of the blood in tissue is substantial.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676658

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat.

Authors:  Sabina H L de Villiers; Nina Lindblom; Genadiy Kalayanov; Sandra Gordon; Anette M Johansson; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-16       Impact factor: 3.000

2.  Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

Authors:  Sabina H L de Villiers; Katherine E Cornish; Andrew J Troska; Marco Pravetoni; Paul R Pentel
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

Review 3.  Imaging of cells and nanoparticles: implications for drug delivery to the brain.

Authors:  Katica Stojanov; Inge S Zuhorn; Rudi A J O Dierckx; Erik F J de Vries
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

4.  A sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies.

Authors:  S Machard; F Theodoro; H Benech; J M Grognet; E Ezan
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound.

Authors:  William J Jusko; Emilie A G Molins; Vivaswath S Ayyar
Journal:  Drug Metab Dispos       Date:  2020-08-05       Impact factor: 3.922

6.  Evaluation and calibration of high-throughput predictions of chemical distribution to tissues.

Authors:  Robert G Pearce; R Woodrow Setzer; Jimena L Davis; John F Wambaugh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-14       Impact factor: 2.745

7.  Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment.

Authors:  Matthew D Thompson; Daniel A Beard
Journal:  J Pharm Sci       Date:  2011-10-03       Impact factor: 3.534

8.  Prediction of in vivo tissue distribution from in vitro data 1. Experiments with markers of aqueous spaces.

Authors:  P Ballard; D E Leahy; M Rowland
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

9.  Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production Rate Data.

Authors:  Yoko Franchetti; Thomas D Nolin
Journal:  J Pharmacol Exp Ther       Date:  2019-08-09       Impact factor: 4.030

10.  Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.

Authors:  Dhaval K Shah; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-12-25       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.